Japanese Encephalitis Vaccines
Inactivated and live-attenuated vaccines
This page catalogs 4 Japanese encephalitis (JE) vaccine products. JE vaccination is recommended for travelers to endemic areas in Asia and the Pacific. The US transitioned from a mouse brain-derived vaccine (JE-Vax) to a Vero cell-derived product (Ixiaro) in the 2000s.
Last updated: April 2026.
Japanese Encephalitis Vaccine Catalog
| Trade Name | Generic Designation | Manufacturer | Vaccine Type | Regulatory Status & Year | Key Notes |
|---|---|---|---|---|---|
| JE-Vax | JE vaccine (mouse brain-derived) | BIKEN/Sanofi | Inactivated (mouse brain) | FDA Licensed; Discontinued 2005 | Replaced by Ixiaro |
| Ixiaro | JE vaccine, inactivated (Vero cell) | Valneva | Inactivated viral | FDA Licensed, 2009 | Current US-licensed JE vaccine |
| Imojev | JE vaccine, live-attenuated chimeric | Sanofi Pasteur | Live-attenuated chimeric | Licensed in Australia/Asia | Chimeric yellow fever/JE |
| JENVAC | JE vaccine, inactivated (Vero cell) | Bharat Biotech | Inactivated viral | Licensed in India | India-developed |
Sources
Regulatory data sourced from FDA CBER Vaccines Licensed for Use in the United States (March 2026), TGA (Australia), and India DCGI records. Catalog scope informed by Khan, Shaz, The Ultimate Vaccine Timeline.